Investigation of the reinforcing potential of samidorphan and naltrexone by fixed and progressive ratio intravenous self-administration testing in heroin-maintained rats

Abstract

Background:

Samidorphan is a novel μ-opioid antagonist with low intrinsic activity at κ- and δ-opioid receptors.

Aims:

Because samidorphan is central nervous system-active, we investigated whether samidorphan (13.6, 40.8, 68 μg/kg/injection) served as a positive reinforcer in rats trained to self-administer heroin on a fixed ratio-5 schedule. Samidorphan’s relative reinforcing effect was evaluated by progressive ratio/break-point determination. Naltrexone (13.6, 40.8, 68 μg/kg/injection) and heroin (7.5, 15, 25 μg/kg/injection) were comparators.

Results:

All heroin doses maintained self-administration on fixed ratio-5 and progressive ratio/break-points at levels significantly greater than saline. Samidorphan and naltrexone had similar profiles on fixed ratio-5 with one samidorphan dose serving as a positive reinforcer and one naltrexone dose showing a strong trend (p=0.053) for positive reinforcement. The numbers of injections of every samidorphan and naltrexone dose were significantly lower than all heroin doses. The numbers of self-administered samidorphan and naltrexone injections/session on fixed ratio-5 were not significantly different from one another. The mean inter-injection intervals for heroin were significantly shorter than for saline, whereas those of samidorphan and naltrexone were not. Progressive ratio break-points for samidorphan and naltrexone were not different from saline except for the highest dose of samidorphan. In addition, the progressive ratio break-points for samidorphan were not significantly different from those of naltrexone and were significantly lower than heroin. The samidorphan unit-doses evaluated in self-administration yielded plasma concentrations ranging between 25–109% and 10–45% of the maximum concentration values in humans.

Conclusions:

Overall, the profiles of samidorphan and naltrexone, which has no abuse liability, were similar in this model.

Keywords

Abuse testing dependence samidorphan heroin naltrexone self-administration

Get full access to this article

View all access options for this article.

References

Altman

Meyer

Mirin

et al . (1976) Opiate antagonists and the modification of heroin self-administration behavior in man: An experimental study. Int J Addict 11: 485–499.

Bidlack

Knapp

Deaver

et al . (2018) In vitro pharmacological characterization of ALKS 5461, a combination of Buprenorphine and Samidorphin, being developed as an adjunctive treatment for major depressive disorder. J Pharmacol Exp Ther 367: 267–281.

Blakesley

Dinneen

Elliott

et al . (1972) Intravenous self-administration of heroin in the rat: Experimental technique and computer analysis. Br J Pharmacol 45: 181P–182P.

Brady

Fishman

(1985) Assessment of drugs for dependence potential and abuse liability: An overview. In: Seiden

Balster

(eds) Behavioral Pharmacology: The Current Status. New York: Alan R. Liss, pp. 361–382.

Braida

Sala

(2002) Role of the endocannabinoid system in MDMA intracerebral self-administration in rats. Br J Pharmacol 136: 1089–1092.

Brooks

Comer

Sullivan

et al . (2010) Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: A quasi-experiment. J Clin Psychiatry 71: 1371–1378.

Caine

Koob

(1994) Effects of mesolimbic dopamine depletion on responding maintained by cocaine and food. J Exp Anal Behav 61: 213–221.

Center for Drug Evaluation and Research/U.S. Food & Drug Administration, U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (2017). Assessment of Abuse Potential of Drugs. Guidance for Industry. www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm334743.pdf (accessed 17 January 2017).

Committee for Medicinal Products for Human Use/ European Medicine Agency, European Medicine Agency, Committee for Medicinal Products for Human Use (2006). Guidance of the Non-clinical Investigation of the Dependence Potential of Medicinal Products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003360.pdf (accessed 17 July 2017).

10.

Cox

Goldstein

Nelson

(1984) Nicotine self-administration in rats. Br J Pharmacol 83: 49–55.

11.

Cunningham

Dean

Todtenkopf

et al . (2014) Samidorphan attenuates drug-induced increases in extracellular dopamine concentrations and drug self-administration in rats. Presented at the European College of Neuropsychopharmacology Annual Meeting, 18–21 October 2014, Berlin, Germany.

12.

Ettenberg

Pettit

Bloom

et al . (1982) Heroin and cocaine intravenous self-administration in rats: Mediation by separate neural systems. Psychopharmacology 78: 204–209.

13.

Ewan

Martin

(2013) Analgesics as reinforcers with chronic pain: Evidence from operant studies. Neurosci Lett 557: 60–64.

14.

Ferrari

Bertolotti

Dell’Utri

et al . (1998) Serum time-course of naltrexone and 6β-naltrexol levels during long-term treatment in drug addicts. Drug Alcohol Depend 52: 211–20.

15.

Fishbain

Rosomoff

Cutler

(1993) Opiate detoxification protocols. A clinical manual. Ann Clin Psychiatry 5: 53–65.

16.

Galloway

Koch

Cello

Smith

(2005) Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial. BMC Psychiatry 5: 18.

17.

Gharagozlou

Demirci

Clark

et al . (2002) Activation profiles of opioid ligands in HEK cells expressing delta opioid receptors. BMC Neurosci 3: 19.

18.

Greenstein

O’Brien

McLellan

et al . (1981) Naltrexone: A short-term treatment for opiate dependence. Am J Drug Alcohol Abuse 8: 291–300.

19.

Harrigan

Downs

(1978) Continuous intravenous naltrexone effects on morphine self-administration in rhesus monkeys. J Pharmacol Exp Ther 204: 481–486.

20.

Heal

Gosden

Smith

(2012) What is the prognosis for new centrally-acting anti-obesity drugs? Neuropharmacology 63: 132–146.

21.

Heal

Gosden

Smith

(2018) Evaluating the abuse potential of psychedelic drugs for medical use in humans. Neuropharmacology 142: 89–115.

22.

Heal

Smith

(2017) Comparison by rat intravenous self-administration (IVSA) of the reinforcing effects of nicotine versus three C-II drugs. Proceedings of the College on Problems of Drug Dependence Meeting, 17–22 June 2017, Montreal, Abstract 248.

23.

Hemby

Dworkin

et al . (1999) Synergistic elevations in nucleus accumbens extracellular dopamine concentrations during self-administration of cocaine/heroin combinations (Speedball) in rats. J Pharmacol Exp Ther 288: 274–280.

24.

Hudzik

Freedman

Palmer

(1996) Remacemide hydrochloride and ARL 15896AR lack abuse potential: Additional differences from other uncompetitive NMDA antagonists. Epilepsia 37: 544–550.

25.

Huskinson

Naylor

Rowlett

et al . (2014) Predicting abuse potential of stimulants and other dopaminergic drugs: Overview and recommendations. Neuropharmacology 87: 66–80.

26.

Kumar

Mumford

Teixeira

(1977) Influencing morphine self-administration in dependent rats. Br J Pharmacol 60: 276P.

27.

Marquis

Webb

Moreton

(1989) Effects of fixed ratio size and dose on phencyclidine self-administration by rats. Psychopharmacology 97: 179–182.

28.

Martin

Kim

Cannon

et al . (2000) Antagonism of δ₂-opioid receptors by naltrindole-5’-isothiocyanate attenuates heroin self-administration but not antinociception in rats. J Pharmacol Exp Ther 294: 975–982.

29.

McMillan

Hardwick

et al . (2004) Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. J Pharmacol Exp Ther 309: 1248–1255.

30.

Niciu

Arias

(2013) Targeted opioid receptor antagonists in the treatment of alcohol use disorders. CNS Drugs 27: 777–787.

31.

Oakley

Cheetham

Heal

et al . (2015) Comparison of the relative reinforcing effects of heroin, remifentanil and morphine using fixed and progressive ratio schedules of reinforcement in rat intravenous self-administration. Poster No 059P. Presented at Pharmacology 2015 (Annual Meeting of the British Pharmacological Society), 15–17 December 2015, London, UK.

32.

O’Connor

Chapman

Butler

et al . (2011) The predictive validity of the rat self-administration model for abuse liability. Neurosci Biobehav Rev 35: 912–938.

33.

Omar

Hoskin

Johnston

et al . (1989) Diamorphine stability in aqueous solution for subcutaneous infusion. J Pharm Pharmacol 41: 275–277.

34.

Padwal

(2009) Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. Curr Opin Investig Drugs 10: 1117–1125.

35.

Roberts

Loh

Vickers

(1989) Self-administration of cocaine on a progressive ratio schedule in rats: Dose-response relationship and effect of haloperidol pretreatment. Psychopharmacology 97: 535–538.

36.

Rocha

Ward

Egilmez

et al . (1996) Tolerance to the discriminative stimulus and reinforcing effects of ketamine. Behav Pharmacol 7: 160–168.

37.

Rothman

Char

et al . (1993) Phenylpiperidine opioid antagonists that promote weight loss in rats have high affinity for the kappa-2B (enkephalin-sensitive) binding site. Peptides 14: 17–20.

38.

Shram

Silverman

Ehrich

et al . (2015) Use of remifentanil in a novel clinical paradigm to characterize onset and duration of opioid blockade by samidorphan, a potent μ-receptor antagonist. J Clin Psychopharmacol 35: 242–249.

39.

Smith

Hirst

Gowdey

(1978) Spontaneous hydrolysis of heroin in buffered solution. Can J Physiol Pharmacol 56: 665–667.

40.

Solinas

Panlilio

Goldberg

(2004) Exposure to delta-9-tetrahydrocannabinol (THC) increases subsequent heroin taking but not heroin’s reinforcing efficacy: A self-administration study in rats. Neuropsychopharmacology 29: 1301–1311.

41.

Tanda

Mereu

Hiranita

et al . (2016) Lack of specific involvement of (+)-naloxone and (+)-naltrexone on the reinforcing and neurochemical effects of cocaine and opioids. Neuropsychopharmacology 41: 2772–2781.

42.

Todtenkopf

Dean

Turncliff

et al . (2008) In vitro and in vivo characterization of novel opioid antagonists. Alcohol Clin Exp Res 32: 11A–271A.

43.

Turncliff

DiPetrillo

Silverman

et al . (2015) Single and multiple dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers. Clin Ther 338–348.

44.

Valentino

Katz

Medzihradsky

et al . (1983) Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonists. Life Sci 32: 2887–2896.

45.

van der Kam

de Vry

et al . (2007) Effect of 2-methyl-6-(phenylethynyl) pyridine on intravenous self-administration of ketamine and heroin in the rat. Behav Pharmacol 18: 717–724.

46.

Wells

(1987) Naltrexone in the treatment of opiate dependence. Br J Hosp Med 37: 469–470.

47.

Wentland

Lou

et al . (2009) Synthesis of novel high affinity ligands for opioid receptors. Bioorg Med Chem Let 19: 2289–2294.

48.

Wentland

Sun

et al . (2005) Redefining the structure-activity relationships of 2,6-methano-3-benzazocines, part 3: 8-thiocarboxamido and 8-thioforamido derivatives of cyclazocine. Bioorg Med Chem Let 15: 2547–2551.